4 completed, 4 terminated, 2 recruiting, 1 active not recruiting. 8 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 3, Recruiting 2, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 8 | Completed 3, Terminated 3, Active not recruiting 1, Recruiting 1 |
Follow Recurrent Waldenstrom Macroglobulinemia: new trials by email Literature Review of Recurrent Waldenstrom Macroglobulinemia trials Research Report on Recurrent Waldenstrom Macroglobulinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 38 | 2026-09-30 | 2026-10-05 |
| Q702 for the Treatment of Patients With Hematologic Malignancies Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration - Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma | Phase 1 | Recruiting | Mayo Clinic | 46 | 2025-08-27 | 2025-10-10 |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 | Withdrawn | Yazeed Sawalha | 2022-09-30 | 2022-09-30 | |
| Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia Ibrutinib, Ixazomib Citrate, Laboratory Biomarker Analysis - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia | Phase 2 | Terminated | Mayo Clinic | 21 | 2018-08-14 | 2026-05-05 |
| Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma Carfilzomib, Laboratory Biomarker Analysis, Rituximab - Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma | Phase 2 | Terminated | University of Washington | 4 | 2017-12-18 | 2020-01-18 |
| Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 150 | 2017-09-11 | 2026-05-14 |
| Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Selinexor - Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Barbara Ann Karmanos Cancer Institute | 43 | 2017-06-20 | 2026-10-23 |
| Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma | Phase 1 / Phase 2 | Completed | David Bond, MD | 36 | 2017-02-14 | 2026-09-23 |
| Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 1 | Completed | Kami Maddocks | 2 | 2017-01-12 | 2019-07-30 |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas Ibrutinib, Idelalisib, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | Mayo Clinic | 65 | 2015-02-19 | 2026-06-24 |
| Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma Bortezomib, Dexamethasone, Laboratory Biomarker Analysis - Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 9 | 2011-07-20 | 2021-10-04 |
| Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia Pomalidomide - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 15 | 2010-10-06 | 2025-09-04 |
Waldenstrom Macroglobulinemia (12) · Lymphoma, B-Cell, Marginal Zone (8) · Lymphoma, Follicular (7) · Lymphoma, Mantle-Cell (6) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, B-Cell (4) · Lymphoma, Large B-Cell, Diffuse (4) · Blastic Plasmacytoid Dendritic Cell Neoplasm (2) · Burkitt Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Myelodysplastic Syndromes (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Erdheim-Chester Disease (1) · Hematologic Diseases (1) · Histiocytic Sarcoma (1)
Blood Protein Disorders (12) · Cardiovascular Diseases (12) · Hemic and Lymphatic Diseases (12) · Hemorrhagic Disorders (12) · Hemostatic Disorders (12) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Lymphatic Diseases (12) · Lymphoproliferative Disorders (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Neoplasms, Plasma Cell (12) · Paraproteinemias (12) · Vascular Diseases (12) · Hematologic Diseases (11)
ibrutinib (3) · Biopsy (2) · CT-P10 (2) · Lenalidomide (2) · Magnetic Resonance Spectroscopy (2) · Rituximab (2) · Sirolimus (2) · Specimen Handling (2) · pembrolizumab (2) · Bortezomib (1) · Calcium Dobesilate (1) · Cyclophosphamide (1) · Cyclosporine (1) · Cyclosporins (1) · Dexamethasone (1)
Mayo Clinic (4) · Barbara Ann Karmanos Cancer Institute (1) · David Bond, MD (1) · Fred Hutchinson Cancer Center (1) · Kami Maddocks (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · University of Washington (1) · Yazeed Sawalha (1)
United States (11)
Asher A. Chanan-Khan, M.D. (1) · David Bond, MD (1) · Dipenkumar Modi, M.D. (1) · Jithma P. Abeykoon, MD (1) · Kami Maddocks, MD (1) · Leonard T Heffner (1) · Masumi Ueda Oshima (1) · Prashant Kapoor, MD (1) · Sheeba K Thomas (1) · Stephen Smith (1) · Wei Ding (1) · Yazeed Sawalha, MD (1)
PMID 28424162, PMID 33785483, PMID 41043099
P30CA015704 (2), P01CA078902 (1), P30CA016058 (1), P30CA022453 (1), P50CA097274 (1), U10CA021115 (1), U10CA180820 (1)